Article
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Leukemia - 1 May 2011
Drakos E, Singh R R, Rassidakis G Z, Schlette E, Li J, Claret F X, Ford R J, Vega F, Medeiros L J
Abstract excerpt
p53 is frequently wild type (wt) in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a is a small molecule that activates the p53 pathway by disrupting p53-MDM2 interaction. We show that nutlin-3a activates p53 in DLBCL cells associated with t(14;18)(q32;q21), BCL2 overexpression and wt p53, resulting in cell cycle arrest and apoptosis. Nutlin-3a treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
